Eli Lilly (LLY) included in 12 Best Stocks to Buy for the Long Term. Signs $1.12 billion deal with Seamless Therapeutics to develop gene-editing treatments for hearing loss. Agreement gives access to enzyme technology for precise DNA changes. Lilly to oversee program from preclinical to commercialization stages. Continues focus on genetic medicines beyond traditional drugs like Zepbound and Mounjaro. Acquired Verve Therapeutics for gene-editing therapies in heart-related conditions.

Read more at Yahoo Finance: Eli Lilly (LLY) Taps Gene-Editing Technology to Target Hearing Loss, Reuters Reports